CR9481A - Mimeticuerpos de peptido similar a glucagon-1 humanos, composiciones, metodos y usos - Google Patents

Mimeticuerpos de peptido similar a glucagon-1 humanos, composiciones, metodos y usos

Info

Publication number
CR9481A
CR9481A CR9481A CR9481A CR9481A CR 9481 A CR9481 A CR 9481A CR 9481 A CR9481 A CR 9481A CR 9481 A CR9481 A CR 9481A CR 9481 A CR9481 A CR 9481A
Authority
CR
Costa Rica
Prior art keywords
methods
compositions
mimeticbodies
glucagon
humans
Prior art date
Application number
CR9481A
Other languages
English (en)
Inventor
T O'neil Karyn
Picha Kristen
Original Assignee
Centocor Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centocor Inc filed Critical Centocor Inc
Publication of CR9481A publication Critical patent/CR9481A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/10—Immunoglobulin or domain(s) thereof as scaffolds for inserted non-Ig peptide sequences, e.g. for vaccination purposes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La presente invencion se refiere por lo menos un mimeticuerpo de GLP-1 humano novedoso o porcion o variante especificada, que incluye acidos nucleicos aislados que codifican por lo menos un mimeticuerpo de GLP-1 o porcion o variante especificada, mimeticuerpo de GLP-1 o porcion o variante especificadas, vectores, celulas hospedero, animales transgenicos o plantas, y metodos para hacer y usar los mismos, incluyendo composiciones terapeuticas, metodos y dispositivos.
CR9481A 2005-03-28 2007-10-29 Mimeticuerpos de peptido similar a glucagon-1 humanos, composiciones, metodos y usos CR9481A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2005097175 2005-03-28

Publications (1)

Publication Number Publication Date
CR9481A true CR9481A (es) 2009-01-14

Family

ID=38256744

Family Applications (1)

Application Number Title Priority Date Filing Date
CR9481A CR9481A (es) 2005-03-28 2007-10-29 Mimeticuerpos de peptido similar a glucagon-1 humanos, composiciones, metodos y usos

Country Status (12)

Country Link
EP (1) EP1871811A4 (es)
JP (1) JP2008546373A (es)
KR (1) KR20080005378A (es)
CN (1) CN101389346A (es)
AU (1) AU2005339797A1 (es)
BR (1) BRPI0520168A2 (es)
CA (1) CA2603359A1 (es)
CR (1) CR9481A (es)
IL (1) IL186307A0 (es)
MX (1) MX2007011975A (es)
NO (1) NO20075272L (es)
WO (1) WO2007081302A2 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200843794A (en) * 2006-12-21 2008-11-16 Centocor Inc Use of long-acting GLP-1 receptor agonists to improve insulin sensitivity and lipid profiles
CN111574583B (zh) * 2020-04-10 2021-06-25 上海海路生物技术有限公司 蛋白复性试剂及其应用
CN120741086A (zh) * 2024-07-26 2025-10-03 荣耀终端股份有限公司 模拟人体组织液及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU3224700A (en) * 1999-02-08 2000-08-25 Chiron Corporation Fibroblast growth factor receptor-immunoglobulin fusion
ES2311560T3 (es) * 2000-12-07 2009-02-16 Eli Lilly And Company Proteinas de fusion glp-1.
BR0312276A (pt) * 2002-06-28 2005-04-26 Centocor Inc Mimeticorpos ch1-removidos miméticos de epo de mamìfero, composições, métodos e usos
CA2490409A1 (en) * 2002-06-28 2004-01-08 Centocor, Inc. Mammalian ch1 deleted mimetibodies, compositions, methods and uses
US20050033029A1 (en) * 2003-06-30 2005-02-10 Jin Lu Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
EA011583B1 (ru) * 2004-03-31 2009-04-28 Сентокор, Инк. Миметические антитела glp-1 человека, композиции, способы и применения

Also Published As

Publication number Publication date
IL186307A0 (en) 2008-01-20
EP1871811A4 (en) 2009-07-22
WO2007081302A3 (en) 2008-11-13
JP2008546373A (ja) 2008-12-25
KR20080005378A (ko) 2008-01-11
NO20075272L (no) 2007-12-28
WO2007081302A2 (en) 2007-07-19
CA2603359A1 (en) 2007-07-19
AU2005339797A1 (en) 2007-07-19
CN101389346A (zh) 2009-03-18
MX2007011975A (es) 2008-03-14
EP1871811A2 (en) 2008-01-02
BRPI0520168A2 (pt) 2009-04-22

Similar Documents

Publication Publication Date Title
UY30494A1 (es) Mimeticuerpos de glp-1 humanos, composiciones, métodos y usos
AR049014A1 (es) Mimeticuerpos de glp-1 humanos , composiciones y usos
CR8320A (es) Mimeticuerpos humanos centrales de la region de bisagra, mimeticos de la eritropoyetina, composiciones, metodos y usos
CR9606A (es) Anticuerpos anti-proteina quinoatrayente de monocitos-1, composiciones, metodos y usos
NI200700158A (es) Agonistas glp-1, composiciones, métodos y usos
NI201000056A (es) Anticuerpos anti-amiloides, composiciones, métodos y usos.
HN2006016512A (es) Anticuerpos anti-il-6, composiciones, metodos y usos
CR9443A (es) Vacuna de toxoide de c. perfringens alfa
CR9514A (es) Antagonistas de npy, preparacion y usos
UY29128A1 (es) Proteinas derivadas de inmunoglobulina específica de il-23p40, composiciones, epitopes, métodos y usos
HN2004000319A (es) "{ 1,8}naftiridin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia"
UY30820A1 (es) Uso de agonistas del receptor de glp-1 de accion prolongada para mejorar la sensibilidad a la insulina y los perfiles lipidicos
HN2003000063A (es) Derivados de nicotinamida y una sal de tiotropio en combinacion para el tratamiento de enfermedades.
NO20075272L (no) Humane GLP-1 "mimetibodies", sammensetninger, fremgangsmater og anvendelser
WO2007076319A3 (en) Human glp-1 mimetibodies and compositions for treating obesity and related disorders, methods and uses
DOP2006000117A (es) Terapia génica de interferon-beta usando un sistema mejorado de expresión regulada
CL2007003811A1 (es) Inhibidores de proteasa no naturales del tipo de kunitz que tienen entre 56-60 aminoacidos; acido nucleico que codifica un inhibidor de proteasa no natural; uso de dicho inhibidor para tratamiento de hemorragias.
UY27973A1 (es) Debencenoxazepinas
AR030133A1 (es) Anticuerpos anti-tnf, composiciones, metodos y usos
UY29552A1 (es) Anticuerpos anti-mcp-1, composiciones, métodos y usos
ES2337005R (es) Compuestos de pirazolina azepan o azocansustituidos, su preparacion y su uso como medicamentos.
DOP2003000696A (es) Debencenoxazepinas
UY29509A1 (es) Anticuerpos anti-il-6, composiciones, métodos y usos
AR030135A1 (es) Anticuerpos de integrina anti-dual, composiciones, metodos y usos
ECSP066772A (es) Compuestos de pirazolina sustituidos para reducir trigliceridos en la sangre

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)